Objectives Patients (pts) with severe eosinophilic asthma (SEA) often have poor disease control
and impaired health-related quality of life. ImPROve Asthma is the first study in
Germany to evaluate PROs and PA in pts receiving benralizumab according to EU label
in a real-world setting.
Methods This is an interim analysis (data-cut: 28-02-2021) of a prospective study observing
patient-reported outcomes (PROs) and physical activity (PA) in uncontrolled SEA patients
treated with benralizumab in Germany. For biologic naïve pts who have completed at
least 1 month of benralizumab treatment, asthma control (using ACT, ACQ-6) and symptoms
(using a visual analogue scale (VAS) from 0 to 10 cm) were analysed. A subgroup (25
pts) using wearable activity trackers were analysed for PA.
Results This analysis included 145 pts (22-90 yrs, median age: 59 yrs, 54.5% women).
After 1 month of treatment, 60.0% of the pts showed a response (increase ≥3 points
from baseline (BL)) in the ACT Score. 39.7% of pts were well-controlled after 1 month: 8.3% improved from partly- to well-controlled,
23.3% from poorly- to well-controlled.
In the ACQ-6 a response was observed in 68.7% of pts, with 4.0% improved from partly- to well-controlled,
and 12.1% from poorly- to well-controlled).
Symptoms improved compared to baseline VAS (median decrease of 2cm) after 1 month.
The above benefits were appreciable at 7 and 14 days.
The PA increased by a median of 1,335 daily steps after 1 month from BL (7,798 daily steps).
Conclusions Majority of patients with severe eosinophilic asthma experienced substantial early
benefit in validated PROs and physical activity after 1 month of benralizumab.
Sponsor of the imPROve asthma study: AstraZeneca
Previously presented at ERS congress 2021
